Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer

We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, K, Yamaguchi, T, Ishihara, T, Sudo, K, Kato, H, Saisho, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361295/
https://www.ncbi.nlm.nih.gov/pubmed/16721372
http://dx.doi.org/10.1038/sj.bjc.6603168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361295/
https://www.ncbi.nlm.nih.gov/pubmed/16721372
http://dx.doi.org/10.1038/sj.bjc.6603168

Ejemplares similares